Does the media favor ASND or ELVN?

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than Enliven Therapeutics. MarketBeat recorded 25 mentions for Ascendis Pharma A/S and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Ascendis Pharma A/S's score of 0.63 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 7 mentions for BridgeBio Pharma and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat BridgeBio Pharma's score of 0.94 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELVN or EXEL?

In the previous week, Exelixis had 23 more articles in the media than Enliven Therapeutics. MarketBeat recorded 28 mentions for Exelixis and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Exelixis' score of 0.24 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 8 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, SMMT or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is SMMT or ELVN more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Enliven Therapeutics N/A -18.55% -18.09%

Does the media favor SMMT or ELVN?

In the previous week, Summit Therapeutics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 10 mentions for Summit Therapeutics and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Summit Therapeutics' score of 0.56 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELVN or BMRN?

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for BioMarin Pharmaceutical and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat BioMarin Pharmaceutical's score of 0.70 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$50.24 +1.12 (+2.28%)

Closing price 04:00 PM Eastern

Extended Trading

$50.02 -0.22 (-0.44%)

As of 04:46 PM Eastern

Compare

ELVN vs. ASND, BBIO, EXEL, SMMT, and BMRN

Should you buy Enliven Therapeutics stock or one of its competitors? Enliven Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Enliven Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$1.05B	14.24	-$258M	$12.89	18.54
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Enliven Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Enliven Therapeutics	N/A	-18.55%	-18.09%

Ascendis Pharma A/S has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 20 more articles in the media than Enliven Therapeutics. MarketBeat recorded 25 mentions for Ascendis Pharma A/S and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Ascendis Pharma A/S's score of 0.63 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S currently has a consensus target price of $310.75, suggesting a potential upside of 30.00%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 49.28%. Given Enliven Therapeutics' higher probable upside, analysts plainly believe Enliven Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

95.1% of Enliven Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Enliven Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to BridgeBio Pharma?

Enliven Therapeutics (NASDAQ:ELVN) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Enliven Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, BridgeBio Pharma had 2 more articles in the media than Enliven Therapeutics. MarketBeat recorded 7 mentions for BridgeBio Pharma and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat BridgeBio Pharma's score of 0.94 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 49.28%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 52.45%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Enliven Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

Enliven Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
BridgeBio Pharma	$502.08M	26.21	-$724.93M	-$3.57	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Exelixis?

Enliven Therapeutics (NASDAQ:ELVN) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Exelixis has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Exelixis	$2.32B	6.25	$782.57M	$3.18	18.39

Enliven Therapeutics currently has a consensus price target of $75.00, indicating a potential upside of 49.28%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 14.03%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Enliven Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Exelixis has a net margin of 35.33% compared to Enliven Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Exelixis	35.33%	42.17%	31.76%

In the previous week, Exelixis had 23 more articles in the media than Enliven Therapeutics. MarketBeat recorded 28 mentions for Exelixis and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Exelixis' score of 0.24 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral

Enliven Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Exelixis beats Enliven Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Enliven Therapeutics (NASDAQ:ELVN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Enliven Therapeutics' return on equity of -18.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Enliven Therapeutics	N/A	-18.55%	-18.09%

In the previous week, Summit Therapeutics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 10 mentions for Summit Therapeutics and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat Summit Therapeutics' score of 0.56 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summit Therapeutics presently has a consensus target price of $25.91, suggesting a potential upside of 46.21%. Enliven Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 49.28%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Summary

Enliven Therapeutics beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Enliven Therapeutics (NASDAQ:ELVN) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, BioMarin Pharmaceutical had 9 more articles in the media than Enliven Therapeutics. MarketBeat recorded 14 mentions for BioMarin Pharmaceutical and 5 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 1.10 beat BioMarin Pharmaceutical's score of 0.70 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	4 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioMarin Pharmaceutical has a net margin of 2.14% compared to Enliven Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Enliven Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 49.28%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 37.02%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enliven Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
BioMarin Pharmaceutical	$3.22B	3.91	$348.90M	$0.37	175.89

Summary

BioMarin Pharmaceutical beats Enliven Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.68B	$3.90B	$7.23B	$15.25B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	-30.08	13.99	274.12	25.56
Price / Sales	N/A	1,417.24	638.35	87.26
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	6.49	15.52	10.51	6.31
Net Income	-$103.69M	-$22.78M	$3.48B	$357.99M
7 Day Performance	-10.65%	-1.29%	0.32%	0.29%
1 Month Performance	-15.61%	-1.44%	-0.22%	-3.14%
1 Year Performance	164.14%	39.76%	22.62%	6.87%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	2.5246 of 5 stars	$50.24 +2.3%	$75.00 +49.3%	+166.5%	$3.68B	N/A	N/A	67	Positive News
ASND Ascendis Pharma A/S	4.6449 of 5 stars	$270.09 -0.2%	$310.05 +14.8%	+25.6%	$16.85B	$1.05B	20.95	1,189	Analyst Downgrade Analyst Revision
BBIO BridgeBio Pharma	3.6019 of 5 stars	$74.76 -0.1%	$101.53 +35.8%	+32.6%	$14.61B	$502.08M	N/A	400	Options Volume Gap Up
EXEL Exelixis	2.4266 of 5 stars	$57.67 -2.3%	$50.07 -13.2%	+45.1%	$14.29B	$2.32B	18.14	1,077	Analyst Forecast
SMMT Summit Therapeutics	2.348 of 5 stars	$17.28 -1.8%	$24.82 +43.6%	-4.5%	$13.79B	N/A	N/A	110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ASND, BBIO, EXEL, SMMT, and BMRN

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Enliven Therapeutics compare to BridgeBio Pharma?

Summary

How does Enliven Therapeutics compare to Exelixis?

Summary

How does Enliven Therapeutics compare to Summit Therapeutics?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. ASND, BBIO, EXEL, SMMT, and BMRN

How does Enliven Therapeutics compare to Ascendis Pharma A/S?

Which has stronger earnings & valuation, ASND or ELVN?

Is ASND or ELVN more profitable?

Which has more risk and volatility, ASND or ELVN?

Does the media favor ASND or ELVN?

Do analysts prefer ASND or ELVN?

Do institutionals and insiders hold more shares of ASND or ELVN?

Summary

How does Enliven Therapeutics compare to BridgeBio Pharma?

Is ELVN or BBIO more profitable?

Does the media prefer ELVN or BBIO?

Do analysts prefer ELVN or BBIO?

Which has more volatility and risk, ELVN or BBIO?

Which has preferable valuation & earnings, ELVN or BBIO?

Do institutionals & insiders have more ownership in ELVN or BBIO?

Summary

How does Enliven Therapeutics compare to Exelixis?

Which has preferable valuation & earnings, ELVN or EXEL?

Do analysts prefer ELVN or EXEL?

Is ELVN or EXEL more profitable?

Does the media refer more to ELVN or EXEL?

Which has more volatility & risk, ELVN or EXEL?

Do institutionals and insiders believe in ELVN or EXEL?

Summary

How does Enliven Therapeutics compare to Summit Therapeutics?

Is SMMT or ELVN more profitable?

Does the media favor SMMT or ELVN?

Which has more volatility & risk, SMMT or ELVN?

Which has preferable earnings & valuation, SMMT or ELVN?

Do insiders and institutionals believe in SMMT or ELVN?

Do analysts recommend SMMT or ELVN?

Summary

How does Enliven Therapeutics compare to BioMarin Pharmaceutical?

Does the media refer more to ELVN or BMRN?

Is ELVN or BMRN more profitable?

Do analysts recommend ELVN or BMRN?

Do institutionals and insiders have more ownership in ELVN or BMRN?

Which has more volatility and risk, ELVN or BMRN?

Which has stronger earnings & valuation, ELVN or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools